āagman

Not investment advice. Data and computed figures, for information only.

Mankind Pharma Ltd

NSE: MANKINDF&O
₹2,347.60
+₹12.60 (+0.54%)
NSE · 15 Oct 2026, close
NSE
As of 31 Mar 2026
Market Cap
₹97,830 Cr
CMP
₹2,347.60
52-wk High / Low
₹2,642 / 1,910
P/E
45.9
P/B
6.0
Book Value
₹395.0
Div Yield
0.04%
ROCE
14.0%
ROE
13.1%
Face Value
₹1
D/E
0.39

Price−4.6% over 1Y

āagman read

Computed by āagman
Derived from 8 years and 14 quarters of filings. Not reported by the company.
As of 15 Oct 2026
How we compute these
Piotroski F-Score
7
/ 9
7 of 9 F-score tests passed
Graham Number
₹642
√(22.5 × EPS × book value per share)
ROIC
10.1%
vs 11.2% sector median
Cash flow to profit
1.61
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+247
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
12.9%
ROE × earnings retention ratio
ROE stability
4.3
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom −0.03FII −0.79DII +0.93
Latest quarter vs the previous one
Cash-accrual divergence
−4.3%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.0x)
+Piotroski F-Score of 7/9 is in the strong band (≥7)
Watch-outs
−Latest ROCE of 14% trails the sector median of 17%
−Promoter holding fell by 2.3pp over the last year

Peer comparison

Peers
NameP/EMar Cap ₹ CrROCE %ROE %

Quarterly results

Consolidated basis (as filed) · ₹ Cr · 13 quarters
As of 30 Jun 2026
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales2,5792,7082,6072,4222,8683,0613,1993,0793,5703,6973,5673,4434,031
Expenses1,9242,0252,0001,8362,1962,2142,3832,3962,7242,7762,6482,5132,974
Operating Profit6556836065866728478166838479219199301,056
OPM %25.4%25.2%23.2%24.2%23.4%27.7%25.5%22.2%23.7%24.9%25.8%27.0%26.2%
Other Income63637594108109872498394−319449
Interest6999117221191171170157142110
Depreciation8796110100103100187231219222223223226
Profit before tax624641562572666849495511540624509659769
Net Profit494511460477543659385425445520414559574
EPS (₹)12.1512.5111.3311.7613.3916.319.2210.2010.6212.399.9013.4313.75

Profit & Loss

As of 30 Jun 2026
Consolidated · ₹ Cr · 8 years + TTM
Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,3345,8656,2147,7828,74910,26012,20714,27814,738
Expenses2,7484,4274,5655,7916,8487,7439,18210,65310,911
Operating Profit5861,4381,6491,9911,9022,5173,0263,6253,827
OPM %17.6%24.5%26.5%25.6%21.7%24.5%24.8%25.4%26.0%
Other Income76122183210141295548238207
Interest22321604634432644579
Depreciation3999119167326378621886893
Profit before tax6211,4381,6921,9751,6712,3992,5212,3332,562
Net Profit4451,0561,2931,4531,3101,9422,0111,9382,068
EPS (₹)219.3325.7231.5935.7832.0047.7548.2646.3449.47

Balance Sheet

As of 30 Jun 2026
Consolidated · ₹ Cr
Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital2040404040404141—
Reserves2,0353,4454,6826,1157,3959,32314,29116,259—
Borrowings01312418731702078,5116,312—
Other Liabilities9681,4491,3972,0802,0802,3134,8085,143—
Total Liabilities3,0225,0656,3609,1089,68611,88327,65227,755—
Fixed Assets3161,6001,6643,5884,2514,54519,00518,620—
CWIP473173727015502828261,128—
Investments9598291,5121,1091,3462,5682,0421,985—
Other Assets1,7002,3192,8113,7093,5384,4885,7806,022—
Total Assets3,0225,0656,3609,1089,68611,88327,65227,755—

Cash Flows

As of 31 Mar 2026
Consolidated · ₹ Cr
Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity—1,0701,1379201,8132,1522,4133,121
Cash from Investing Activity—−436−1,222−1,369−1,052−2,081−12,624−181
Cash from Financing Activity—−531−8605−740510,233−2,953
Net Cash Flow—103−92156227722−12

Ratios

As of 31 Mar 2026
8 periods
Mar 2015Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %——37.032.022.026.017.014.0
ROE %———————13.1
EPS (₹)219.3325.7231.5935.7832.0047.7548.2646.34
Book Value (₹)———————395.0
Face Value (₹)———————1
P/E———————45.9
Div Yield %———————0.04
NPM %13.017.620.218.214.718.415.813.4
OPM %18.025.027.026.022.025.025.025.0
D/E0.000.040.050.140.020.020.590.39
P/B———————6.0

Growth

As of 11 Oct 2026
Compounded sales growth
5 years+18.0%
3 years+18.0%
TTM+14.0%
Compounded profit growth
5 years+11.0%
3 years+17.0%
TTM+13.0%
Stock price CAGR
3 years+10.0%
Last year−4.0%
Return on equity
5 years17.0%
3 years16.0%
Last year13.0%

Shareholding pattern

As of 30 Jun 2024
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters74.88%74.88%72.70%72.66%72.63%
FIIs9.87%9.87%12.92%10.24%9.45%
DIIs11.14%11.14%11.47%14.46%15.39%
Government—————
Public4.10%4.10%2.89%2.63%2.53%
No. of shareholders1,35,1161,35,1161,80,5971,77,6061,66,715
Change since Jun 2023 (pp)
Promoters −2.25FIIs −0.42DIIs +4.25Public −1.57

Documents

As of 11 Oct 2026
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Board Meeting Intimation for Adoption Of Unaudited Financial ResultsResignation Of Statutory Auditors Of A Material WOSClosure of Trading WindowShareholder Meeting / Postal Ballot-Scrutinizer"s Report
Annual reports
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023
Credit ratings
Rating updateRating updateRating updateRating updateRating update
Concalls
Aug 2026TranscriptAug 2026PPTAug 2026RecordingMay 2026TranscriptMay 2026PPTMay 2026RecordingFeb 2026TranscriptFeb 2026PPTFeb 2026RecordingNov 2025TranscriptNov 2025PPTNov 2025RecordingAug 2025TranscriptAug 2025PPTAug 2025Recording

Corporate actions

As of 8 Aug 2025
8 Aug 2025DIVIDENDInterim Dividend - Re 1 Per Share—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman